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Abstract: Acquired QT syndrome is mainly caused by the administration of drugs that prolong ventricular repolarization. 
On the other hand, the risk of drug-induced torsades de pointes is increased by numerous predisposing factors, such as 
genetic predisposition, female sex, hypokalemia and cardiac dysfunction. This adverse reaction is induced by different 
chemical compounds used for the treatment of a variety of pathologies, including arrhythmias. As it is known, 
antiarrhythmic agents and other cardiovascular drugs can prolong the QT interval, causing this adverse reaction. Of the 20 
most commonly reported drugs, 10 were cardiovascular agents and these appeared in 348 of the reports (46%). Class Ia 
antiarrhythmic agents have frequently been linked to inducing arrhythmia, including torsades de pointes. Sotalol and 
amiodarone, class III antiarrhythmics, are known to prolong the QT interval by blocking IKr. Due to the severity of events 
caused by the therapeutic use of these drugs, in this work of revision the cardiovascular drugs that present this property 
and the factors and evidence will be mentioned. 
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INTRODUCTION 
 The prolongation of the QT interval of the 
electrocardiogram has either a congenital origin due to 
mutations in ion channels or an acquired origin, generally 
due to the administration of QT-prolonging drugs [1]. The 
prolongation of this segment is related to the appearance of 
early post-potentials and the increase of the dispersion of the 
QT period in the different layers of the myocardium [1]. 
These electrophysiological abnormalities give rise to TdP, 
also called polymorphic ventricular tachycardia, which 
usually causes syncope, ventricular fibrillation and sudden 
death [2]. This adverse reaction is induced by different 
chemical compounds used for the treatment of a variety of 
pathologies, including arrhythmias. As it is known, 
antiarrhythmic agents and other cardiovascular drugs can 
prolong the QT interval, causing this adverse reaction. Due 
to the severity of events caused by the therapeutic use of 
these drugs, in this work of revision the cardiovascular drugs 
that present this property and the factors and evidence will 
be mentioned. 
DRUGS THAT MAY CAUSE QT PROLONGATION 
OR TORSADES DE POINTES 
 In his review, Darpö [3] wrote that, in all, 225 
pharmaceutical compounds have been associated with 
torsades de pointes (TdP) in spontaneous adverse reaction 
reports collected by the WHO Drug Monitoring Centre. Of 
the 20 most commonly reported drugs, 10 were 
cardiovascular agents and these appeared in 348 of the 
reports (46%). 
 On the other hand, several drugs have been withdrawn 
from the U.S. market or have received black box warnings 
due to their potential to cause QT interval prolongation that  
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leads to fatal ventricular arrhythmias and sudden cardiac 
death [4, 5]. Table 1 lists some cardiovascular drugs capable 
of prolonging the QT interval. 
Table 1. Antiarrhythmic and Cardiovascular Drugs that 
Induce QT Prolongation 
 
Generic Name Risk 
Antiarrhythmics 
 Amiodarone A 
 Disopyramide A 
 Dofetilide A 
 Flecainide B 
 Ibutilide A 
 Procainamide A 
 Quinidine A 
 Sotalol A 
Cardiovasculars 
 Bepridil A 
 Dobutamine B 
 Dopamine B 
 Adrenaline B 
 Indapamide B 
 Isradipine B 
 Moexipril B 
 Nicardipine B 
A: Drugs with a risk of Torsades de Pointes. 
B: Drugs with a possible risk of Torsades de Pointes. 
C: Drugs with a conditional risk of Torsades de Pointes. 
Source: www.torsades.org (June 17 2009) 
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 The ability of a drug to prolong the QT period is related to 
the interference of inward and outward ionic currents in 
ventricular action potential [6]. Most of the drugs that exhibit 
this property increase the duration of the action potential by 
reducing the delayed rectifier potassium current, due to a 
blockade of the current’s rapid component (IKr) [7]. 
 In the ventricles, loss of function mutations in the genes 
which encode K
+
 channels and drugs (mainly HERG channel 
antagonists) are related to hereditary and acquired long QT 
syndrome, respectively, that put individuals at high risk for 
developing TdP arrhythmias and life-threatening ventricular 
fibrillation [8]. Similarly, K
+
 channel down-regulation in heart 
failure also increases the risk of sudden death [8]. 
 On the other hand, the prolongation of the QT period of the 
electrocardiogram is used as a marker of a drug’s ability to 
induce TdP [4]. Nevertheless, the relation between the 
prolongation of the QT interval and the incidence of this 
arrhythmia is imperfect. Drugs like amiodarone and verapamil, 
which prolong the interval significantly, show a low incidence 
of polymorphic ventricular tachycardia [9]. This is explained 
because these drugs present other actions, such as the blockade 
of L-type calcium channels which diminish the capacity to 
cause early post-potentials [10]. This suggests that it is 
important to consider not only a drug’s ability to prolong the QT 
interval, but also possible pharmacological properties that 
diminish the alterations of the increase of action potential 
duration. It is currently generally accepted that the dispersion of 
the QT interval caused by a drug may be a more reliable 
parameter of the potentiality of a drug to cause TdP, since a 
greater dispersion of the QT interval facilitates the maintenance 
of this arrhythmia by a re-entry mechanism [11]. The incidence 
of TdP due to clinical drug use prolonging the QT interval is not 
well known [12]. The data of incidence of this adverse reaction 
are obtained mainly from spontaneous reports of adverse events. 
According to an epidemiological study carried out in Sweden, 
the incidence of TdP is estimated to be 10 times greater than the 
incidence reported [13]. In the case of antiarrhythmic drugs, like 
quinidine, the incidence of this adverse reaction is higher than 
1% [5]. The incidence of this proarrhythmia due to class III 
antiarrhythmic drugs varies from drug to drug. Sotalol and 
dofetilide present a 3% risk, whereas amiodarone and azimilide 
present an extremely lower incidence [14]. This smaller 
incidence may be related to the ability of amiodarone and 
azimilide to block the rectifier current, Ikr as well as Iks [14]. 
 Because the information on drug-associated TdP is 
constantly growing in line with the increasing awareness and 
concern, we kindly ask the reader to use the Internet for updates. 
The www.torsades.org website provides updated information 
about QT-prolonging agents. 
FACTORS FOR DRUG-INDUCED QT PROLONGAT-
ION AND TORSADES DE POINTES 
 Table 2 [5, 15] shows some risk factors for induction of long 
QT intervals and TdP. Factors include genetic predisposition, 
gender, drug use, drug interactions and cardiac abnormalities. 
Genetic Predisposition 
 It is widely known that congenital long QT syndrome is 
related to the existence of mutations in ion channels that take 
part in the processes of depolarization and repolarization of  
 
Table 2. Some Risk Factors for Drug-Induced Torsades de 
Pointes [5,15] 
 
- Congenital long QT 
- Female gender 
- Hypokalemia, hypomagnesemia and hypocalcemia) 
- Diuretics 
- Bradycardia 
- Cardiac hypertrophy and myocardial fibrosis 
- Congestive heart failure 
- Renal and liver insufficiency 
- Co-administration of agents blocking P450 isoenzyme CYP3A4 
- Baseline electrocardiographic abnormalities 
 
myocardial cells, which is also a factor in drug-induced TdP 
[8, 16]. On the other hand, although these mutations are rare 
(1 in 500 patients) [16], the existence of patients with ion 
channel mutations that present subclinical long QT 
syndrome has been established in recent years [17, 18]. 
Although these patients present a normal or slightly 
increased QT interval, they are more likely to exhibit QT 
interval prolongation from exposure to drugs, since they 
would present a reduced repolarization reserve [19]. 
Therefore, whereas the administration of QT-prolonging 
drugs would have minimum effects in normal patients, in 
patients with silent ion channel mutations, the administration 
of these drugs would cause an exaggerated prolongation of 
this interval and a greater risk of proarrhythmia [19]. A 
possible explanation may be the presence of a subclinical 
mutation of the intervening ion channel in the slow 
component of the delayed rectifier current (IKs). This 
mutation would not be significant in normal conditions due 
to the predominant role of IKr in repolarization, but it would 
be substantial if it was blocked. The presence of silent 
mutations was identified in 15% of patients with acquired 
long QT syndrome [20, 21]. On the other hand, genetic 
alterations also affect the plasma elimination of drugs, giving 
rise to greater plasma drug levels and a greater risk of TdP. It 
is known that the increase of plasma levels of most QT-
prolonging drugs is dose-dependent, thus causing a greater 
prolongation of ventricular repolarization [22]. Two 
metabolic enzymes that present genetic polymorphism are 
CYP2D6 and CYP2C cytochrome P450 isoforms [22, 23]. 
Thus, there are people with fast metabolism with an enzyme 
with normal metabolic capacity, and people with slow 
metabolism with an aberrant enzyme. In Caucasians, the 
population with slow metabolism represents between 5% and 
10% of total population. Several QT-prolonging drugs are 
metabolized by the CYP2D6 and CYP2C enzymes. These 
patients, when presenting deficient purifying capacity, will 
present high plasma levels and a greater risk of dose-
dependent adverse reactions. Another protein involved in 
pharmacokinetic processes is P-glycoprotein, which takes 
part in the body’s drug extrusion in the gastrointestinal tract 
and the kidneys [24]. A fraction of the P-glycoprotein 
population expresses one anomalous transporter, presenting 
a smaller capacity of extrusion and therefore increased 
plasma levels of those drugs that are substrates for this 
glycoprotein, such as amiodarone, digoxin and quinidine 
[25]. 
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Physiological and Pathological Factors 
 The QT interval of the electrocardiogram and its drug-
induced prolongation can be increased by physiological and 
pathological factors. It is widely known that women present 
a longer QT interval than men, besides exhibiting a greater 
susceptibility to drug-induced prolongation [14]. Two thirds 
of the cases of TdP induced by reported drugs were observed 
in women [14]. On the other hand, anorexia nervosa, which 
affects 1% of young women, causing sudden death in a 
significant percentage of patients, appears to be related to an 
additional prolongation of the QT interval, which could be 
explained by electrolyte disorders as well as by unknown 
factors [26]. Bradycardia also favors the prolongation of the 
QT interval, which suggests that the effect drug-induced 
prolongation will be marked in patients with bradycardia or 
atrioventricular conduction problems [27]. Since the length 
of the interval is dependent on the heart rate, the interval 
should be corrected [28]. Other widely-known factors are 
electrolyte disorders. Hypokalemia and hypomagnesemia 
favor a greater prolongation by drugs [5, 15, 29, 30]. Renal 
and hepatic perfusion is reduced in patients with cardiac 
dysfunction, favoring smaller systemic drug elimination 
[14]. 
 Myocardial alterations induced by acute myocardial 
infarction and left ventricular hypertrophy also favor a 
greater prolongation of the QT interval, as well as a greater 
dispersion between the different layers of myocardial cells 
[31]. On the other hand, heart failure causes an exaggerated 
prolongation of repolarization in canine Purkinje fibers [32]. 
 Various forms of cardiac disease and rhythm 
disturbances result in altered ion channel and transporter 
function. These alterations appear in many instances to be 
part of the homeostatic adaptive response to the primary 
dysfunction, but then results in secondary cardiac 
dysfunction, including tachyarrhythmias. So, heart disease 
modifies the operation of ion channels and transporters in a 
way that induces the occurrence of rhythm disturbances 
through the arrhythmogenic remodeling process [33]. 
 K
+
 currents play an important role in shaping the cardiac 
action potential, and remodeling-induced changes in K
+
 
currents are important contributors to repolarization 
abnormalities associated with heart failure. Some of the 
changes in heart failure mimic congenital channelopathies 
that produce long QT syndromes, and congestive heart 
failure can be viewed like an acquired QT prolongation [33, 
34]. Down-regulation of transcript expression plays a role in 
the changes in K
+
 current function associated with heart 
failure. Posttranscriptional and posttranslational mechanisms 
may be important in heart failure-related IKs down-
regulation, a fact that would not be surprising in view of the 
regulation of IKs function by associated proteins in 
macromolecular complexes [33,35]. The down-regulation of 
K
+
 currents can promote arrhythmogenic early afterdepolar-
izations, either by prolonging action potential duration in the 
voltage range at which ICaL reactivation generates 
afterdepolarizations or by reducing the repolarization reserve 
[36-38]. 
 On the other hand, cardiac failure has effects on cellular 
Ca
2+
 handling. Triggered activity related to delayed 
afterdepolarizations caused by spontaneous diastolic Ca
2+ 
release is a mechanism underlying ventricular arrhythmias 
induced by cardiac failure [33, 39, 40]. Delayed 
afterdepolarizations occur in congestive cardiac failure 
despite reduced Ca
2+ 
stores because of some features of heart 
failure-induced ion transport remodeling [33, 40-42]: I) 
hyperphosphorylated Ca
2+
 release channels are prone to 
spontaneous diastolic Ca
2+ 







 exchange function increases 
the depolarizing current resulting from electrogenic Ca
2+
 
extrusion, and III) IK1 down-regulation increases membrane 
resistance, resulting in a larger depolarization for a given 
inward current. 
 In the ventricle, electrical remodeling has been related to 
changes in T-wave morphology [43]. Moreover, ventricular 
remodeling is associated with prolongation of repolarization 
[44-46]. Rapid ventricular pacing for shorts periods (1 h) can 
cause changes in ventricular repolarization and changes in 
activation sequence over 3 weeks was associated with 
reduced expression of Ito and Ito channel mRNA [44-46]. On 
the other hand, the electronic load imposed by a change in 
activation sequence reduces the upstroke amplitude, which, 
in turn, attenuates Ito triggering down-regulation of the ionic 
current [47]. 
DRUG INTERACTIONS 
 The simultaneous use of drugs that induce prolongation 
of the QT interval is another risk factor for TdP. This risk 
factor can be avoided by the correct prescription of drugs. 
Drug-induced prolongation of the QT interval can be 
increased by the joint administration of another drug with the 
same pharmacodynamic property, or drugs that inhibit the 
systemic elimination of drugs that reduce plasma potassium 
levels [12]. On the other hand, agents with sympathomimetic 
activity also promote drug-induced TdP, since they increase 
calcium influx through L-type channels [10]. Numerous 
reports have shown a risk of proarrhythmia increased by 
association of two drugs that prolong ventricular 
repolarization [12]. Considering the high rate of prescription 
of these drugs, and that they are used for the treatment of 
different pathologies, it would not be strange for a patient to 
be prescribed two drugs with the same property. Viskin et al. 
[12] reviewed the reports of 229 cases of drug-induced TdP, 
finding that in 39% there had been joint administration of 
two QT-prolonging drugs. It is also worth noting that this 
drug interaction is easily avoidable by knowing the 
pharmacodynamic properties of interacting drugs. Listings of 
QT-prolonging drugs are available on websites such as 
www.torsades.org, which is regularly updated. Consulting 
these bibliographical sources could help avoid this type of 
potentially fatal drug interaction. In addition, if a patient who 
is under treatment with a QT-prolonging drug requires the 
administration of a drug of another pharmacological class, 
the physician should select the drug within the class with the 
smaller potential for prolonging ventricular repolarization. A 
great amount of QT-prolonging drugs is eliminated through 
hepatic metabolism by various cytochrome P450 isoforms. 
So, it has been demonstrated that the administration of 
erythromycin (a CYP3A4 inhibitor) significantly increases 
the levels of quinidine (a substrate of the CYP3A4 enzyme), 
increasing the risk of TdP [48, 49]. 
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 We also need to consider that several drugs, including 
thiazide diuretics and  agonists, cause hypokalemia and 
therefore exacerbate the drug-induced prolongation of the 
QT interval [50]. For example, the diuretic indapamide 
induces hypokalemia and blocks the slow component of the 
delayed rectifier K
+
 current (IKs) and potentiates the effects 
of sotalol, leading to excessive lengthening of cardiac 
repolarization and to the development of TdP [51, 52]. 
ANTIARRHYTHMIC AND CARDIOVASCULAR 
DRUGS THAT MORE COMMONLY CAUSE 
TORSADES 
Antiarrhythmic Drugs 
 Class Ia antiarrhythmic agents have frequently been 
linked to inducing arrhythmia, including TdP, by blockade of 
K
+
 current, similarly to class III agents [3, 53, 54]. Sotalol 
and amiodarone, class III antiarrhythmics, are known to 
prolong the QT interval by blocking the IKr. However, the 
risk of TdP with amiodarone is low when compared with 
sotalol [3, 53, 54]. Higher drug concentrations of sotalol can 
lead to QTc intervals that are prolonged by approximately 10 
to 40 milliseconds, thereby increasing the incidence of TdP. 
With the exception of quinidine, the degree of QT 
prolongation linked to the antiarrhythmics depends on the 
serum drug level [55]. 
 On the other hand, the class III agents blocking the IKr 
and the human channel is encoded by the human ether-a-go-
go-related gene (HERG) [8, 56]. The inhibition of HERG K
+
 
currents causes lengthening of the cardiac action potential 
and may produce beneficial class III antiarrhythmic effect. In 
contrast, an excessive reduction of these currents due to 
either genetic defects or adverse drug reactions can lead to 
hereditary or acquired long QT syndrome and an increased 
risk for TdP and sudden death [8, 56]. 
Class I Antiarrhythmic drugs 
 Disopyramide is a well-known antiarrhythmic agent with 
several indications for the treatment of arrhythmias [57]. 
Some precautions are electrocardiogram, monitoring and 
dose adjustment to prevent QT prolongation, and the 
correction of hypokalemia before initiating therapy [57, 58]. 
 Disopyramide inhibits HERG-encoded potassium 
channels at clinically relevant concentrations and this action 
may constitute the molecular basis for acquired LQTS 
associated with this drug [59]. 
 The class I antiarrhythmic agent procainamide is used for 
the treatment of ventricular tachycardia, premature 
ventricular contractions, paroxysmal atrial tachycardia, etc., 
and it is known to induce prolongation of the QT interval 
[10, 57]. Ellebongen et al. [60] recommend that patients 
being started on antiarrhythmic therapy with procainamide 
be admitted to the hospital for monitoring to ensure that their 
QT interval is not excessively prolonged. 
 Foo and Nq [61] reported the case of a 43-year-old 
Chinese woman who complained of a one week history of 
irregular rapid palpitations associated with chest discomfort 
and dyspnea, and a wide complex tachycardia with a slightly 
irregular rhythm. Delta waves were also present. When she 
was treated with intravenous procainamide, she developed 
TdP secondary to prolonged QT interval. 
 In their review about quinidine, Grace and Camm [62] 
wrote that syncope and sudden death have been recognized 
as potential complications of quinidine therapy and both are 
usually due to polymorphic ventricular tachycardia. The use 
of quinidine, one of the earliest antiarrhythmic drugs 
developed, fell dramatically in favor of newer antiarrhythmic 
medications when increased risk of ventricular arrhythmia 
and death with quinidine emerged [62, 63]. However, at this 
time there is a renewed interest in the use of quinidine. In 
particular, quinidine appears to be safe and efficacious in 
combination with verapamil for the treatment of atrial 
fibrillation. Quinidine has also been used successfully to 
treat idiopathic ventricular fibrillation, Brugada syndrome, 
and short QT syndrome [63]. 
 TdP by quinidine also occurs during long-term treatment, 
usually in association with an identifiable trigger. It may 
occur in patients with a structurally normal heart but is more 
likely to occur in those with heart-muscle disease, in patients 
given quinidine combined with digoxin, or those with 
hypokalemia or hypomagnesemia [62]. It has been 
demonstrated that an inhibitor of the CYP3A4 significantly 
increases the levels of quinidine, increasing the risk of TdP 
[48, 49]. 
 Quinidine-associated TdP is more common in women 
than in men, as is TdP associated with other antiarrhythmic 
drugs, possibly because of estrogen-dependent delayed 
repolarization [62]. It was estimated that quinidine can cause 
TdP in 1% to 8% of patients, even at lower doses [3].
 
The 
degree of QT prolongation linked to quinidine does not 
depend on the serum drug level [55, 62]. 
 Flecainide is a class Ic antiarrhythmic agent that can 
block the delayed rectifier potassium current [64]. This agent 
is used as a provocative test to unmask the electrocardiogram 
(ECG) phenotype of the Brugada syndrome, as well as long-
term treatment for long QT-3 syndrome, since it also 
shortens the QT interval [65]. Mutations of the cardiac 
sodium channel gene, SCN5A, are present in both long QT 
and Brugada syndromes [66]. Recently, Bernart et al. [67] 
reported a case where oral flecainide induced syncope with a 
Brugada ECG pattern in a patient with known long QT-3 
syndrome. 
Class III Antiarrhythmic Drugs 
 In their report, Letsas et al. [68] investigated the 
causative medications and underlying risk factors that 
predisposed to drug-induced QT interval prolongation in 
twenty-one patients with drug-induced long QT (90% 
females, mean age 64.3 ± 14.1 years). They reported that 
known cardiac agents (mainly class III antiarrhythmics) were 
implicated in 13/21 (62%), antipsychotics in 8/21 (38%), and 
antibiotics in 5/21 patients (24%). These authors observed a 
significant correlation between administration of cardiac 
agents and TdP events (P < 0.05). 
 Most of these class III agents, e.g. dofetilide, d-sotalol 
and sematilide, are powerful IKr blockers, but other 
mechanisms may also contribute to the antiarrhythmic 
effects (as may be the case with, for example, ibutilide and 
azimilide) [56]. Moreover, IKr is encoded by the HERG 
related gene and class III antiarrhythmic agents inhibit the 
HERG currents [56]. With amiodarone, the incidence of TdP 
is very low [69]. In several clinical trials, no proarrhythmia 
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occurred during treatment with intravenous amiodarone for 
conversion of atrial arrhythmias to sinus rhythm [70-72]. 
With d,1-sotalol, the incidence of TdP is about 2% [73-76]. 
With dofetilide, ibutilide and almokalant, the incidence 
varies between 1% and 8% [3]. 
 Dofetilide is a highly specific class III 
methanesulfonanilide antiarrhythmic drug. This drug 
selectively blocks the rapid component of the cardiac ion 
channel delayed rectifier current and it works by selectively 
blocking the rapid component of the delayed rectifier 
outward potassium current, IKr [56]. The drug appears to 
primarily block activated channels and has a much lower 
affinity for closed and inactivated channels [77]. At 
nanomolar concentrations, this agent prolongs both the atrial 
and ventricular effective refractory periods and AP duration. 
Dofetilide does not appear to interact with other cardiac ion 
channels, and this explains its minimal effects upon 
conduction velocity, myocardial contractility and systemic 
hemodynamics. Dofetilide prolongs the QT interval with 
little effect on QT dispersion. No effect was observed on 
conduction parameters PA, AH, M HV, PR or QRS 
intervals, sinus cycle length or sinus node recovery [56]. 
 In the Symptomatic Atrial Fibrillation Investigation 
Research on Dofetilide (SAFIRE-D) trial, the drug was 
evaluated for its ability to convert and maintain SR in 
patients with chronic atrial fibrillation (AF) (85% of 
patients) or atrial flutter. After the first 105 patients were 
enrolled, the dosing protocol was altered to adjust for 
baseline renal function (creatinine clearance) and change in 
QTc interval duration. There were two cases of nonfatal TdP 
considered a result of dofetilide therapy; both occurred 
within the first 3 days of therapy [56]. Prolongation of QTc 
duration accounted for 10 withdrawals, and one SD 
occurred. Dosage adjustment based on creatinine clearance 
or QTc prolongation was required in 33% of patients. As a 
result of this trial, starting therapy in the hospital and 
adjusting dosage based on creatinine clearance and QTc 
prolongation are required to minimize the risk of 
proarrhythmia [56]. 
 Like other class III drugs, the prolonged QT interval 
occurring in the patients treated with dofetilide can be 
complicated by TdP. The incidence of TdP is dose-
dependent, and is 0.3–10.5%. The risk appears to be dose-
dependent, with an increased incidence of TdP associated 
with higher doses of dofetilide administered. The risk of 
inducing TdP can be decreased by taking precautions when 
initiating therapy, such as hospitalizing individuals for a 
minimum of three days for serial creatinine measurement, 
continuous telemetry monitoring and availability of cardiac 
resuscitation. Severity of heart failure (HF), female gender, 
and QTc duration make it possible to identify patients with a 
high risk of early TdP when treated with dofetilide. Patients 
with recent myocardial infarction (MI) had TdP less often 
compared with patients with chronic HF [78]. 
 Ibutilide is a selective class III antiarrhythmic agent that 
when administered intravenously can terminate AF and atrial 
flutter. It is an antiarrhythmic medication that helps return 
the heart to its normal sinus rhythm [56, 57]. Ibutilide 
reduces abnormal electrical signals that cause AF by 
stabilizing the heart muscle tissue. Ibutilide is given 
intravenously. It acts for only a short period. The drug is 
used for the cardioversion of atrial flutter and AF, but it can 
cause TdP [56, 57]. 
 Ibutilide may cause many side effects. It should be used 
carefully, and patients should be closely monitored for a 
minimum of 4 h in the hospital after receiving ibutilide. 
Cardiac side effects of ibutilide include rapid, uncontrolled 
heart rhythm: ventricular tachycardia (VT), nonsustained 
monomorphic VT, TdP or ventricular fibrillation (VF) [56, 
57]. 
 Higher drug concentrations of sotalol can lead to QTc 
intervals that are prolonged by approximately 10 to 40 
milliseconds, thereby increasing the incidence of TdP [55]. 
The incidence of sotalol-induced TdP is 0.3% for a daily 
dose of 80 mg, ~1% for patients taking between 160 and 240 
mg/day, and up to 5–7% for a daily dose of 480–640 mg 
[54]. The risk is much higher in women and those with renal 
or congestive heart failure, sustained ventricular tachycardia, 
and with concomitant use of diuretics and hypokalemia [54]. 
 Recently, the review study by Aström-Lilja et al. [79] of 
the Swedish pharmacovigilance database reported that, 
among a total of 61,788 adverse reactions recorded between 
1991 and 2006, 88 cases of TdP were identified. In these 
cases, 27 different suspected drugs were implicated. Cardiac 
drugs were involved in most reports (74%; 65/88), with 
sotalol being the most frequently suspected drug (57%, 
58/88). 
 In a case report of cardiac side effects of sotalol, 
Srivastava et al. [80] reported that a 44 year-old woman 
anesthetized for a transplant nephrectomy, had several runs 
of ventricular tachycardia followed by ventricular fibrillation 
requiring 30 s of cardiopulmonary resuscitation, after which 
she reverted to sinus rhythm. Subsequent investigation found 
that she had toxic serum levels of sotalol, with a prolonged 
corrected QT interval on the electrocardiogram. She was 
started on sotalol while her renal graft was functioning well 
but it was not reviewed when the graft started to fail and she 
had to commence hemodialysis. This led to the accumulation 
of sotalol and explains her serum sotalol value of 7.1 mg/l on 
the day of the event and concentrations greater than 2.5 mg/l 
are generally considered toxic. 
 Yalta et al. [81] reported a case with a severely 
prolonged QT interval and TdP after an initial intake of low 
dose sotalol (80 mg), indicating a probable inherent 
individual oversensitivity to sotalol. Letsas et al. [82], 
regarding this last report, suggested that pharmacologic 
challenge with sotalol may successfully identify patients 
with normal QTc intervals and reduced repolarization 
reserve that are at increased risk to develop drug-induced 
long QT syndrome and TdP. 
 A curious case of suicide attempt was reported by 
Cherpanatath et al. [83]. These authors reported that a 62-
year-old man was brought into the intensive care unit 
because of a cardiac arrest. After extensive resuscitation, 
including defibrillation, sinus bradycardia occurred with 
marked QT prolongation, followed by recurrent episodes of 
TdP. The hetero-anamnestic data revealed a suicide attempt 
with sotalol. 
 Although amiodarone is approved by the US Food and 
Drug Administration (FDA) only for refractory ventricular 
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arrhythmias, it is one of the most frequently prescribed 
antiarrhythmic medications in the United States. 
Amiodarone is among the most effective with the additional 
advantage of having little proarrhythmic potential [56]. The 
favorable efficacy profile of amiodarone during electrical 
remodeling, particularly the marked increase in amiodarone 
on atrial refractory periods prolongation in early electrical 
remodeling, may explain its superior clinical efficacy over 
existing antiarrhythmic drugs [84]. 
 Amiodarone has a low incidence of cardiac adverse 
events. With amiodarone, the incidence of TdP is very low 
[3, 54]. In seven clinical trials, with a total of 882 patients, 
no proarrhythmia occurred during treatment with intravenous 
amiodarone for conversion of atrial arrhythmias to sinus 
rhythm [3]. 
 In elderly women long-term amiodarone treatment could 
result of combined block of the rapid and slow delayed 
outward potassium current components, translated to the 
ECG in a (more than expected) prolonged QT interval, an 
augmented transmural dispersion of repolarization (TDR) 
and an interrupted T-wave [56]. The unequal regression of 
repolarization lengthening made it possible to individualize 
IK current components in the inscription of the interrupted T-
wave, which argues against the U-wave as a separate entity. 
Silent ion channel gene mutations or polymorphisms and 
down-regulation of beta-adrenergic activation of IKs may 
underlie the unusual repolarization behavior. The unequal 
regression over time of amiodarone induced repolarization 
lengthening could have clinical significance [56, 85]. 
CALCIUM ANTAGONISTS 
 Bepridil is a calcium antagonist which in some countries 
is labeled for use only in patients who are refractory to other 
antianginal drugs. Although it is no longer sold in the United 
States, it has been discussed as a possible option for the 
treatment of atrial fibrillation [86]. 
 Bepridil is a multi-channel blocker acting to block 
calcium, potassium and sodium channels, and has 
characteristics similar to those of class III antiarrhythmic 
drugs. Reports have shown that bepridil also affects 
pharmacological cardioversion in a manner similar to that of 
class III antiarrhythmic drugs. Bepridil’s success rate is, at 
most, 34–58%; hence, the conversion effect of bepridil alone 
is not always satisfactory [87-89]. 
 Bepridil prolongs the QT interval and several cases of 
TdP have been described. In particular, sinus bradycardia 
and a prolonged QT interval are known proarrhythmic 
effects of bepridil, and the administration of bepridil at high 
doses is associated with the development of TdP [90, 91]. 
Yasuda et al. [91] have reported that TdP appeared in 
approximately 1% of patients with atrial flutter or fibrillation 
who received bepridil. They described torsades de pointes as 
manifesting with hypokalemia, particularly in elderly female 
patients. 
DIURETICS 
 Diuretic-induced hypokalemia is believed to be the 
common underlying mechanism of TdP under certain 
circumstances. Indapamide-induced syncope has been 
described in a patient with long QT syndrome, and has been 
attributed to electrolyte disturbances (hypokalemia) [92]. 
 Indapamide also displays direct effects on ionic currents. 
This diuretic blocks the slow component of the delayed 
rectifier K
+
 current (IKs) and potentiates the effects of 
dl-sotalol on ventricular repolarization, leading to excessive 
lengthening of cardiac repolarization and predisposing to the 
development of TdP [51, 52]. Indapamide has been shown to 
inhibit the Na
+





 currents in atrial myocytes [93]. 
 Letsas et al. [94] described a drug interaction with 
indapamide. It was a case of acquired long QT and TdP 
ventricular tachycardia in a woman with systemic lupus 
erythematosus and hypertension receiving prednisolone and 
indapamide. 
MISCELLANEOUS 
 Ambasilide is a class III antiarrhythmic which has been 
shown to block multiple cardiac channels including beta-
adrenergic antagonism. Although the electrophysiological 
effects of ambasilide are characterized on the cellular level, 
its effects on an organ level have yet to be investigated. 
Ambasilide prolonged the RR, PQ, QRS, QT, and QTc in a 
concentration-dependent manner in either normal SR or with 
reduced heart rate (atriotomy). dP/dtmin was increased 
(became less negative) in the presence of increasing 
concentrations of ambasilide, whereas the vehicle produced 
less negative lusitropy. 
 Ambasilide demonstrated use dependence by prolonging 
QTc less at slower heart rates [56, 95]. 
 Sematilide, a close structural analog of N-
acetylprocainamide, is a class III agent which acts largely by 
delaying conduction. The electrophysiological profile of 
sematilide is consistent with the selective block of outward 
potassium currents and associated isolated lengthening of the 
ventricular effective refractory period and AP duration [56]. 
 Sematilide exerts class III actions in patients: it prolongs 
QTc in a dose- and concentration-related fashion, does not 
alter PR or QRS, and slows heart rate at high concentrations. 
The relations between dose and total area under the time-
concentration curve, dose and peak plasma concentration, 
and peak plasma concentration and increase in QTc were 
linear. QTc increases of approximately equal to 25% were 
seen at plasma concentrations of approximately equal to 2.0 
mg/mL. The mean elimination half-life was 3.6 ± 0.8 h, and 
most of a dose (77 ± 13%) was recovered unchanged in the 
urine [56, 96]. 
 Plasma concentrations greater than or equal to 0.8 
mg/mL suppressed arrhythmias (5 patients) or aggravated 
them (3 patients), including 1 patient who needed 
cardioversion for an episode of TdP (2.7 mg/mL) [56, 97]. 
 Mibefradil, a T channel blocker, was withdrawn after 
only one year on the market, largely due to numerous drug-
to-drug interactions, since it inhibited both CYP3A4 and 
2D6 isoenzymes [98]. Mibefradil also gave rise to QT 
prolongation and marked T-wave morphological changes 
that resembled those seen with selective class III 
antiarrhythmics, and this caused a considerable debate as to 
whether the drug had proarrhythmic potentials. There were 
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several reports of TdP in patients on mibefradil during its 
short time on the market, but it is not fully clear whether it 
was a proarrhythmic propensity of the drug or 
pharmacokinetic interactions with other drugs that prolonged 
the QT interval. In either case, it is noteworthy that the 
combination of mibefradil and class I and III antiarrhythmics 
was particularly harmful in a large trial on 2,590 patients 
with congestive heart failure [99]. 
 Miyajima et al. [100] examined the effect of the 
angiotensin II receptor blocker valsartan on QT dispersion 
and the relationship between oxidative stress and QT 
dispersion in patients with essential hypertension. These 
authors concluded that antihypertensive therapy with 
valsartan reduces QTc dispersion and this may be related to 
the ability of valsartan to reduce oxidative stress in patients 
with essential hypertension. 
 Recently Abraham et al. [101] reported that exposure to 
catecholamines and beta-receptor agonists used routinely 
during procedures and diagnostic tests can precipitate all the 
features of stress cardiomyopathy, including cardiac 
isoenzyme elevation, QTc interval prolongation, and rapidly 
reversible cardiac dysfunction. 
 On the other hand, in a recent case report, Quan et al. 
[102] informed that, strikingly, QTc prolongation was 
induced along with syncope after dobutamine infusion in a 
patient with a mutation of the KNCQ1-gene encoding serine 
instead of glycine. 
 Aliskiren, not yet approved by the FDA for the treatment 
of hypertension, manages hypertension by direct renin 
inhibition [57]. The side effect profile for aliskiren has not 
yet been fully described. Recently Peitz et al. [103] 
described the first apparent report of aliskiren-induced QT 
prolongation resulting in TdP. 
THERAPY: -BLOCKER EFFICACY IN THE 
TREATMENT OF LONG QT SYNDROME 
 -blocker efficacy in long QT syndrome type 1 is good 
but variably reported, and the causes of cardiac events 
despite beta-blocker therapy have not been ascertained. 
Recently Vincent et al. (2009) [104] carried out a 
retrospective study of the details surrounding cardiac events 
in 216 genotyped long QT syndrome type 1 patients treated 
with -blocker and followed up for a median time of 10 
years. Twelve patients (5.5%) suffered cardiac arrest 
(CA)/sudden death, but 11 of 12 (92%) were noncompliant 
(n=8), were on a QT-prolonging drug (n=2), or both (n=1) at 
the time of the event. The risk for CA/sudden death in 
compliant patients not taking QT-prolonging drugs was 
dramatically less compared with noncompliant patients on 
QT-prolonging drugs (odds ratio, 0.03; 95% confidence 
interval, 0.003 to 0.22; P=0.001). None of the 26 patients 
with CA before beta-blocker had CA/sudden death on beta-
blockers. These authors state that -blockers are extremely 
effective in long QT syndrome type 1 and should be 
administered at diagnosis and ideally before the preteen 
years. Moreover, -blocker noncompliance and use of QT-
prolonging drug could be responsible for almost all life-
threatening "beta-blocker failures" [104]. 
 On the other hand, the aim of a study by Erdil et al. [105] 
was to evaluate whether esmolol has an effect on QT interval 
during induction of anesthesia using etomidate and fentanyl 
in patients with known coronary artery disease. Sixty 
patients were prospectively randomized to either a control 
group or the esmolol group. In the esmolol group, QTc 
interval was significantly shorter compared to the control 
group (p < 0.05). The authors conclude that infusion of 
esmolol attenuated the QTc interval prolongation associated 
with tracheal intubation. 
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